APA (7th ed.) Citation

Bergmann, L., Albiges, L., Ahrens, M., Gross Goupil, M., Boleti, E., Gravis, G., . . . Haanen, J. (2025). 2600MO Relevance of the CPS score and tumor nephrectomy in the SUNNIFORECAST trial comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer. Annals of Oncology, 36, S1394. https://doi.org/10.1016/j.annonc.2025.08.3216

Chicago Style (17th ed.) Citation

Bergmann, L., et al. "2600MO Relevance of the CPS Score and Tumor Nephrectomy in the SUNNIFORECAST Trial Comparing Ipilimumab/nivolumab Versus Standard of Care in Non-clear Cell Renal Cell Cancer." Annals of Oncology 36 (2025): S1394. https://doi.org/10.1016/j.annonc.2025.08.3216.

MLA (9th ed.) Citation

Bergmann, L., et al. "2600MO Relevance of the CPS Score and Tumor Nephrectomy in the SUNNIFORECAST Trial Comparing Ipilimumab/nivolumab Versus Standard of Care in Non-clear Cell Renal Cell Cancer." Annals of Oncology, vol. 36, 2025, p. S1394, https://doi.org/10.1016/j.annonc.2025.08.3216.